New Triple-Action antibody targets Hard-to-Treat blood cancers

NCT ID NCT05652335

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-phase study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells in people with relapsed or refractory multiple myeloma or AL amyloidosis. About 180 participants will receive the drug to find a safe dose and check for side effects. The goal is to control the disease, not cure it, as ongoing treatment may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis amyloidosis plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREVIOUSLY TREATED AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

CHU Lyon Sud
RECRUITING

Pierre-Bénite, 69495, France
CHU Nantes
RECRUITING

Nantes, 44093, France
CHU de Liege
RECRUITING

Liège, 4000, Belgium
Chu Rennes Hopital Pontchaillou
COMPLETED

Rennes, 35000, France
City of Hope
RECRUITING

Duarte, California, 91010, United States
City of Hope Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
Clinica Univ. de Navarra
RECRUITING

Pamplona, 31008, Spain
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Hosp Clinic de Barcelona
RECRUITING

Barcelona, 08036, Spain
Hosp Clinico Univ de Salamanca
RECRUITING

Salamanca, 37007, Spain
Hosp Univ Fund Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hosp. Univ. Germans Trias I Pujol
RECRUITING

Badalona, 08916, Spain
Icahn School of Medicine at Mt. Sinai
RECRUITING

New York, New York, 10029, United States
Institut Claudius Regaud
RECRUITING

Toulouse, 31100, France
Japanese Red Cross Medical Center
RECRUITING

Shibuya City, 150-8935, Japan
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28001, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Osaka University Hospital
RECRUITING

Suita-shi, 565-0871, Japan
Royal Marsden Hospital
RECRUITING

Sutton, SM2 5PT, United Kingdom
The Cancer Institute Hospital of JFCR
COMPLETED

Tokyo, 135-8550, Japan
UMC Utrecht
RECRUITING

Utrecht, 3584 CX, Netherlands
UZ Antwerpen
RECRUITING

Edegem, 2650, Belgium
UZ Gent
RECRUITING

Ghent, 9000, Belgium
Universitair Medisch Centrum Groningen
RECRUITING

Groningen, 9713 GZ, Netherlands
University College Hospital
RECRUITING

London, W1T 7HA, United Kingdom
University of California San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
VUMC Amsterdam
RECRUITING

Amsterdam, 1081 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.